Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16040428 | 0.84 | MEN1 (0.57) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL17775441 | 0.83 | MEN1 (0.47) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL13851053 | 0.82 | LMNA (0.50) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL16342378 | 0.81 | LMNA (0.48) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL15123629 | 0.80 | MAPT (0.46) | LMNAMEN1KMT2ACTSVCTSL | |
| SCHEMBL12763816 | 0.78 | MEN1 (0.56) | LMNAMEN1KMT2ACTSVCTSL | |
| SCHEMBL6361504 | 0.78 | MEN1 (0.56) | LMNAHPGDMEN1KMT2ACTSV | |
| SCHEMBL26113307 | 0.78 | CTSV (0.50) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL31352860 | 0.78 | CTSV (0.50) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL527106 | 0.78 | CTSV (0.52) | MEN1KMT2ACTSVCTSLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | LMNA 1988/4885HPGD 189/4885ALDH1A1 920/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | LMNA 1801/4885HPGD 230/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.